INTRODUCTION
Cystic fibrosis is an autosomal recessive disease and a hereditary disease of mucus and sweat glands caused by a CF transmembrane regulator defect that mainly affects the respiratory and gastrointestinal systems, leading to progressive disability (1, 2) . According to WHO, 1 in 2000-3000 newborns is affected by CF across the Europe; in north America the incidence has been reported to be 1 in 3500; no accurate data are available in Africa; in middle east various incidence rates have been reported ranging from 1 in 2560 to 1 in 15876 (3) . However these statistics differ from country to country. For example the incidence reported for Ireland, UK, Belgium, Spain are 2.98, 1.37, 1.03, 0.546 in ten thousand respectively (4) . No data are available for Iran in the report of CF by WHO (3) . However there are a few papers reporting different statistics of CF in different regions of Iran. For instance, while no confirmed case of CF has been reported in southern Iran (5), there is a report from north-west of Iran on CF prevalence of 7.98 in 100 thousand during the 5-year period (2004) (2005) (2006) (2007) (2008) (6) in addition to a study reported growth pattern and nutritional intake of 34 infants with CF in East Azerbaijan province (7).
Moreover, spectrum of CFTR gene mutations in 200 Iranian Azeri Turkish Patients with Cystic Fibrosis has been examined and reported in another study (8) .
Registries are considered essential tools designed to measure all health-related aspects of cystic fibrosis (CF) and to compare clinical data from different centers and countries. Over the last 25 years, several national registries of CF have been set up (9) . European Committee of Experts on Rare Diseases emphasizes the importance of the registry system on rare diseases such as CF. This is due to the fact that the registry system can be very useful in cases of rare disease such as cystic fibrosis in providing an integrated resource for improving patient care and research on the disease (10, 11) .
Minimum Data Set is a common set of data items that should be used to collect and report data in the registry (12) . To best of our knowledge, no research has been undertaken so far in order to identify minimum data set for cystic fibrosis in Iran. This paper represents our attempt to identify minimum data set for cystic fibrosis registry system in Northwest of Iran.
METHODS
To determine the minimum data set required for establishing registry system of cystic fi brosis, the systems of selected countries including Netherlands (13), the US (14), Ireland (15) , UK (16) , France (17, 18) , Australia (19) , Brazil (20) , Canada (21), Belgium (22) and New Zealand (23) as well as the registry system of European Cystic Fibrosis Society (24) were studied.
Considering the commonalities and diff erences observed among data elements of the studied registry systems and regional demands, an initial set of data elements was proposed by the researchers. Then a group of multidisciplinary experts consisted of epidemiologists, pediatricians, and CF specialists were asked to review and score the initial set based on their importance by using a nine-point Likert scale ranging from 1 to 9 where 1 referred to concept of "no important for inclusion in MDS" and 9 indicated the statement of "highly important for inclusion in MDS". Data elements that were scored as important or highly important by more than 50 percent of the experts were included in the fi nal minimum data set.
In next stage of the research, availability of data on the agreed minimum data set was evaluated through reviewing the medical records of 144 patients (191 episode of care) hospitalized with diagnosis of cystic fi brosis in Tabriz children hospital from 2009 to 2014.
RESULTS

Identifi cation of initial data elements
Overall six classes of data (including 46 data items) were identifi ed in the selected cystic fi brosis registry systems: patient demographics, administrative data, survival status, diagnostic procedures, genetic and clinical manifestations, and therapeutics. Overall 34 data elements were determined as an initial set as follows: Data elements scored as highly important or important at least by more than 50 percent of the experts are presented in table 1.
Availability of the data
As fi gure 1 depicts availability of data in administrative category and survival class is 100 percent. Collecting data on medications was feasible in 100% of the cases as well. In class of demographic data, availability of patient name, age, gender, place of birth, and date of birth was 100 percent. In group of diagnostic procedures, partial availability of data was observed for sweat and genetic test. However no data were found on antenatal screening, exercise tolerance test, and glucose tolerance test.
DISCUSSION
This paper represents the fi rst attempt undertaken to develop minimum data set for registry system of cystic fi brosis in Northwest of Iran. Comparative study of the registry systems provided a foundation for defi ning the initial MDS. There were six diff erent classes of data elements including patient Table 1 . Minimum data set approved by the experts for CF registry Figure 1 . Percentage of the data availability for CF registry in patient records demographics, administrative data, survival data, diagnostic procedures, genetic and clinical manifestation, and therapeutics. Majority of data elements from all six classes were evaluated as highly important or important by the experts. This is similar to the classes of data determined as minimum data set for athlete health records (25) , physiotherapy (26) , breast cancer (27) , orthopedic injuries in Iran (28), nursing (29) by their related experts. This is also in line with information classes found in data content residing in GP systems (30) . This can reflect the importance of these categories in different domains of health care system. This can be also due to the fact that minimum data set can be used in variety of use cases: for patient care in individual level; for assessment of system and care provider in organizational level; and for national and international comparisons in aggregated level (12) . Moreover minimum data set can contribute to realization of conceptual interoperability throughout all these levels (31).
Reviewing medical records of patients with CF revealed availability of the data in real world. Majority of data in administrative and demographic categories were highly available in the patient records. This is viable as the data items such as patient identification code, patient name and encounter date are important for linking records from multiple resources (32) or data items such as age, gender,or birth place can be used for standard sociodemographic comparisons or reports as they are among high priority data items determined by CF data network (33) . However it should be noted that patient identification code used in the medical records could only identify patient in the hospital not throughout the entire health system. Therefore the unique patient identification number with capability of recognizing patient across the entire health system is the missing element.
High priority given by the experts on date and cause of death and their full availability are in consistent with legal enforcement for recording such data (34) . Medication data were found to be available in 100 percent of the cases. This is not surprising as these data are at the core of the direct patient care.
Partial availability of data for sweat test and genetic test was observed. Although sweat test is done for diagnosing all cases, and genetic test is carried on for most of the patients, but in most cases it is conducted in outpatient services and clinics that are not connected with the inpatient services and their results are usually kept by patient's family. This may also be attributed to lack of linkage or integration among different information silos across CF care related centers, including the laboratories or clinics. This may also reflect lack of appropriate data flow. Use of unique patient identifier across the whole continuum of health system can facilitate data flow and integration of patient care.
Despite high priority given to data items on diagnostic tests such as antenatal screening, exercise tolerance test and glucose tolerance test, no data was found on them in the hospital patient records. It should be noted that the problem with glucose tolerance occurs after age of 10 while all cases in this study are neonates and infants when they are diagnosed or admitted to the hospital. Exercise tolerance test is not a routine test and in case it is done, its data is not entered into hospital records as it is undertaken in private clinics. Antenatal screening is not also done because there is no precise statistic of patients with CF in Iran. Unavailability of data on FEV1 and FVC is due to the fact that respiratory tests are not taken place in hospital but in private ambulatory services and clinics.
Lack of data on organ transplant is not surprising as the lung transplant for patients with CF has just newly introduced in Iran.
Finding about data availability in this research was restricted to children hospital records. Other resources in genetic laboratory centers, or clinics, or other related centers and hospitals were not studied. Lack of unique patient identifier across the entire health system seems to be the most important limit in integrating the related information resources. In addition lack of coding practice for ambulatory and outpatient health services makes it unfeasible to locate and retrieve data residing in the related centers.
CONCLUSION
This study presents minimum data set required for establishing cystic fibrosis registry in Northwest of Iran. Minimum data set can be also useful in designing electronic patient records or registry for those suffering from CF toward integration of their fragmented records across continuum of the health care system and for the shared patient care.
